Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Price-Hiking Drug CEO Creates Cloud Over Antibiotic Industry

Sept. 14, 2018, 9:29 PM

The latest price hike of the generic antibiotic nitrofurantoin isn’t doing any public relations favors for the already withering antibiotic industry.

The global backlash of Nostrum Pharmaceuticals’ 400 percent price spike adds fuel to the raging drug-price debate in the U.S. in which most politicians and patients argue drug prices are too high. Drug companies get even more flak for price hikes for drugs they didn’t develop, which is the case for Nostrum’s nitrofurantoin.

While the sticker price of Nostrum’s generic antibiotic has risen substantially, the antibiotic industry overall has seen waning profit margins for years. Over the past ...